Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) [RETIRED]
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of autonomic and urologic disorders and low back and head pain.
Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and the selected indications. Authors reviewed, abstracted, and classified articles based on the quality of the study (Class I–IV). Conclusions and recommendations were developed based on the highest level of evidence and put into current clinical context.
Results: The highest quality literature available for the respective indications was as follows: axillary hyperhidrosis (two Class I studies); palmar hyperhidrosis (two Class II studies); drooling (four Class II studies); gustatory sweating (five Class III studies); neurogenic detrusor overactivity (two Class I studies); sphincter detrusor dyssynergia in spinal cord injury (two Class II studies); chronic low back pain (one Class II study); episodic migraine (two Class I and two Class II studies); chronic daily headache (four Class II studies); and chronic tension-type headache (two Class I studies).
Recommendations: Botulinum neurotoxin (BoNT) should be offered as a treatment option for the treatment of axillary hyperhidrosis and detrusor overactivity (Level A), should be considered for palmar hyperhidrosis, drooling, and detrusor sphincter dyssynergia after spinal cord injury (Level B), and may be considered for gustatory sweating and low back pain (Level C). BoNT is probably ineffective in episodic migraine and chronic tension-type headache (Level B). There is presently no consistent or strong evidence to permit drawing conclusions on the efficacy of BoNT in chronic daily headache (mainly transformed migraine) (Level U). While clinicians’ practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.
This guideline is retired. The recommendations and conclusions are no longer considered valid and no longer supported by the AAN. Retired guidelines should be used for historical reference only. Please see AAN current guidelines here: https://www.aan.com/policy-and-guidelines/guidelines/.
Letters: Rapid online correspondence
- Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based
- Alexander Mauskop, New York Headache Center, 30 East 76 Street, New York, NY 10021drmauskop@nyheadache.com
- Ninan Mathew
Submitted July 14, 2008 - Reply from the authors
- David M. Simpson, Department of Neurology, Mount Sinai Medical Center, One Gustave Levy Place; Box 1052, New York, NY 10029david.simpson@mssm.edu
- Markus Naumann, Charles Argoff, Casey Childers, Janis Miyasaki, Stephen Silberstein, and Yuen So
Submitted July 14, 2008
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Alert Me
Recommended articles
-
Articles
Dynamic optimization of chronic migraine treatmentCurrent and future optionsNinan T. Mathew et al.Neurology, February 02, 2009 -
Articles
Chronic migraine is an earlier stage of transformed migraine in adultsM. E. Bigal, A. M. Rapoport, F. D. Sheftell et al.Neurology, November 21, 2005 -
Articles
Tracing transformationChronic migraine classification, progression, and epidemiologyRichard B. Lipton et al.Neurology, February 02, 2009 -
Articles
Head or neck injury increases the risk of chronic daily headacheA population-based studyJames R. Couch, Richard B. Lipton, Walter F. Stewart et al.Neurology, September 10, 2007